Aminophylline for prevention of bradyarrhythmias induced by rheolytic thrombectomy.


In patients with acute ST-elevation myocardial infarction or in those with thrombus-containing lesions, percutaneous coronary intervention (PCI) represents a clinical challenge to the interventionist, because coronary thrombus is a predictor of adverse outcomes. Thrombectomy, or the removal of thrombusfrom the infarct-related vessel prior to PCI, might improve clinical outcomes. The AngioJet Rheolytic Thrombectomy System (Possis Medical, Inc., Minneapolis, Minnesota) is commonly used to treat lesions containing thrombus burden. A complication of rheolytic thrombectomy is transient cardiac rhythm disturbances, specifically bradyarrhythmia requiring temporary pacing. Aminophylline, a methylxanthine and a competitive inhibitor of the adenosine receptor, may prevent rheolytic thrombectomy-associated bradyarrhythmias. This report describes the use of aminophylline alone to prevent rheolytic thrombectomy-induced bradyarrhythmias in a single tertiary care center.

Cite this paper

@article{Delago2008AminophyllineFP, title={Aminophylline for prevention of bradyarrhythmias induced by rheolytic thrombectomy.}, author={Augustin J Delago and Mohammad El-Hajjar and Mikhail Kirnus}, journal={The Journal of invasive cardiology}, year={2008}, volume={20 8 Suppl A}, pages={9A-11A} }